These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8585734)

  • 21. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
    Wu YL; Scott EM; Po AL; Tariq VN
    APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
    Bonfiglio G
    Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa].
    Murase M; Miyamoto H; Handa T; Saheki S; Takeuchi N
    Jpn J Antibiot; 1995 Oct; 48(10):1581-9. PubMed ID: 8544340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.
    Segatore B; Setacci D; Perilli M; Franceschini N; Marchetti F; Amicosante G
    Int J Antimicrob Agents; 2000 Jan; 13(3):223-6. PubMed ID: 10724029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
    Croize J; Gout JP; Robert J; Le Noc P
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):573-7. PubMed ID: 2508041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
    Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
    J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Larsson AJ; Rotschafer JC
    J Antimicrob Chemother; 1996 Apr; 37(4):703-10. PubMed ID: 8722536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
    Strenkoski-Nix LC; Forrest A; Schentag JJ; Nix DE
    J Clin Pharmacol; 1998 Nov; 38(11):1063-71. PubMed ID: 9824789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
    Spangler SK; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):772-5. PubMed ID: 8851609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.
    Zelenitsky S; Ariano R; Harding G; Forrest A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4009-14. PubMed ID: 16189073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
    Bonacorsi S; Fitoussi F; Lhopital S; Bingen E
    Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
    Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.
    Segatore B; Setacci D; Perilli M; Franceschini N; De Santis A; Marchetti F; Amicosante G
    Antimicrob Agents Chemother; 1999 Feb; 43(2):428-31. PubMed ID: 9925553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test.
    Braveny I; Machka K; Milatovic D
    Eur J Clin Microbiol; 1986 Feb; 5(1):119-23. PubMed ID: 3084241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
    Khalil H; Chen T; Riffon R; Wang R; Wang Z
    Antimicrob Agents Chemother; 2008 May; 52(5):1635-41. PubMed ID: 18285485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.